Search results
Results From The WOW.Com Content Network
Shares of Geron (NASDAQ: GERN) finished the week ended June 7 about 32% higher. The market was reacting to news the company's investors had been waiting to hear for decades. On June 6, the U.S ...
The biotech needs a win soon.
(Reuters) -Shares of Geron surged more than 20% on Friday, a day after the company gained its first approval from the U.S. Food and Drug Administration for its blood disorder drug.
Geron Corporation has sponsored human clinical trials of several potential anti-cancer products. Imetelstat (GRN163L) is a drug that targets telomerase. [13] In studies conducted at Johns Hopkins University, GRN163L was active against both CD138+ and CD138neg cancer stem cells and eliminated the colony forming potential of both by five weeks. [14]
Geron's stock has rebounded nicely in the first half of 2019. Skip to main content. Sign in. Mail. 24/7 Help. For premium support please call: 800-290-4726 more ways to ...
Geron (GERN) delivered earnings and revenue surprises of 18.18% and 23%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
The red-hot stock is reversing course. For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us